Skip to main content

St. Louis-based biotech startup C2N Diagnostics snags $2.2M in funding to advance Alzheimer's blood test

The Alzheimer’s Drug Discovery Foundation, based in New York, said the funding is targeted toward advancing clinical validation and deployment of C2N’s PrecivityAD blood test for Alzheimer’s disease.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.